# Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

> **NCT05266404** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** Dapagliflozin/sitagliptin FDC
- **DRUG:** Sitagliptin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT05266404
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-21
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266404, "Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05266404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*